



**SDI FINAL EVALUATION FORM 1.1**

**PART 1:**

Journal Name:	<a href="#">Journal of Advances in Medicine and Medical Research</a>
Manuscript Number:	Ms_JAMMR_49377
Title of the Manuscript:	The effect of phosphodiesterase type5 inhibitors on the development of retinopathy of prematurity: A Randomized Clinical Trial

**PART 2:**

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<p>1. What is Ahvaz? If it is a Hospital state the name in full including where it is located</p> <p>2 Move the statement in line 26 to 22, its part of the study design, not a result.. Line 22 should start with "There was no differences....."</p> <p>3. In line 203 , you should open with what Sildenafil is...and its primary use. The pharmacological partway of Sildenafil must be explained alongside the pathophysiology of ROP in DISCUSSION.</p> <p>4, So what is the recommendation? Do we use the drug in patients with ROP with or without caution?. Write at list, a line statement on recommendation</p>	<p>We thank you for taking the time to review our manuscript, and we also Thank you very much for this valuable comment.</p> <p>Here you can find our responses to reviewer's comments. We hope that we have successfully addressed all the raised concerns.</p> <ol style="list-style-type: none"> <li>1- We changed the title to The effect of phosphodiesterase type5 inhibitors on the development of retinopathy of prematurity in Imam Khomeini Hospital's, Ahvaz, Iran preterm infants: A Randomized Clinical Trial</li> <li>2- we moved 52 patients in sildenafil and 50 patients in placebo group were studied in to line 22</li> <li>3- We add Sildenafil citrate has been shown to oral therapy for erectile dysfunction in a wide range of patients with erectile dysfunction. Sildenafil also is able to reduce pulmonary hypertension (PH) which is an important predictor of mortality in chronic obstructive pulmonary disease (COPD)</li> <li>4- The long-term safety of sildenafil is not established, and concerns about side effect are being raised. These side effects could be minimized in a designer drug by combining the principle of selective PDE inhibition with target organ-restricted drug delivery, minimizing systemic actions perhaps by rapid drug metabolism. So Further work on the retinal effects of sildenafil may be useful and with the result of this study we can't recommend it</li> </ol>